Abstract. The present study aimed to investigate the effect of protease-activated receptor 2 (PAR-2) on cell proliferation, invasion and metastasis in the esophageal EC109 cell line. Two short hairpin RNA (shRNA) expression plasmids were constructed based on the PAR-2 mRNA sequence in humans, and they were transfected into the EC109 esophageal cancer cell line, and the stable interference cell line (shRNA -PAR-2 EC109) was obtained by puromycin selection. Following transfection of PAR‑2 shRNA‑1, PAR‑2 expression was significantly downregulated in mRNA level and protein level in EC109 cells (P<0.05). The proliferation of EC109 cells transfected with PAR‑2 shRNA was significantly lower than the negative control group (P<0.05). At 24, 48 and 72 h, the ratio of proliferation inhibition was 15.92, 24.89 and 32.28%, respectively. Compared with the control group, S-phase arrest was observed in cells transfected with shRNA -PAR-2. The ratio of cells in the S phase was 32.79±4.06, 26.54±1.37 and 33.45±2.46% at 24, 48 and 72 h, respectively. For invasion, the number of invasive cells was significantly lower in shRNA ‑PAR2‑2 cells compared with the control group (P<0.05). For metastasis assay, the number of invasive cells was significantly lower in shRNA ‑PAR2‑2 cells compared with the control group (P<0.01). In the present study, the PAR-2 shRNA plasmid was constructed successfully, which can significantly downregulate PAR-2 expression in EC109 cells. Subsequent to silencing of PAR-2, the proliferation of EC109 cells was inhibited and the capabilities of invasion and migration were reduced. It is indicated that PAR-2 may be a potential target in esophageal cancer.

Introduction

Esophageal cancer is one of the most common malignant tumors in the clinic. The incidence of esophageal cancer is the 8th highest in malignant tumors and the mortality rate ranks the 6th highest worldwide (1). In China, the morbidity of esophageal cancer, particularly esophageal squamous cell carcinoma, is very high (2). In the early stage no specific clinical manifestations in patients of esophageal cancer are evident (3). Approximately 80% patients are in advanced or late stage when diagnosed, and the majority of patients cannot be treated with surgery (4). Invasion and metastasis of esophageal cancer in patients is an important factor affecting treatment efficacy and induced poor prognosis (4). It is important to investigate the molecular mechanisms of proliferation-, invasion- and metastasis-associated genes in esophageal cancer, which may provide evidence to prevent and cure esophageal cancer.

Protease activated receptor-2 (PAR-2) is one type of receptor on the cell surface of numerous cells and it belongs to the superfamily of G protein-coupled protease-activated phase receptor (5). Trypsin, tryptase and coagulation factors are the natural agonists for PAR-2, and activated PAR-2 is involved in a series of biological behaviors, including cell proliferation, invasion and metastasis in tumors (6,7). Our previous study found that PAR-2 performed important roles in growth, invasion and metastasis of the esophageal cancer EC109 cell line (8). The present study aimed to investigate whether PAR-2 effects cell characteristics of EC109 through RNA interference technology. A PAR-2 targeted short hairpin RNA (shRNA) vector was constructed and transfected into the EC109 cell line. The silencing effect of PAR-2 shRNA on its target gene was then observed.

Materials and methods

Cell line and plasmid. The esophageal cancer EC109 cell line, E. coli top 10 strain and pGFP-V-RS plasmid were provided by the Department of Cell Biology in Logistics University of People’s Armed Police Force (Tianjin, China). The DH5α competent cell was bought from Transgene Biotech Co., Ltd. (Beijing, China).

Construction of vector. The sequence of human PAR-2 mRNA (gene ID, 55065) was retrieved from the GeneBank database
(https://www.ncbi.nlm.nih.gov/gene/55065). Subsequent to selecting a suitable target site, two oligonucleotide sequences were synthesized: Sequence 1, 5’-TTCTAACTCTGGCC TTGGTGTGGCACAT-3’; sequence 2, 5’-GTGTTTCTCA TAGTGAAAGGGCTGCAAG-3’, while another one non-specific sequence (5’-GCCTGTGACCTCTAATGTC ACTTTCTC-3’) was synthesized, all of these sequences were supplied by OriGene Technologies, Inc. (Rockville, MD, USA). The shRNA stem-loop structure was TCAAGAG, and restriction sites of BamHI and HindIII were introduced at the 5’ and 3’ ends, respectively. The sequences were then connected to the pGFP-V-RS plasmid vector. The recombinant plasmids were transformed to DH5α competent cells. Briefly, the competent cells (100 µl) were incubated with pGFP-V-RS plasmid vector (5 µl) on ice for 30 min following, followed by 42°C for 45s and ice bathed for 2 min. Subsequently, 500 µl SOC medium (Zhongaobio Company, Tianjin, China) was added and mixed. The mixture was centrifuged at 37°C and 40 x g for 1 h. The product then was transferred to a Kana resistant (30 µg/ml) preloaded lysogeny broth (LB) medium plate and incubated overnight at 37°C. Three monoclonal colonies were selected on each dish and were inoculated with 3 ml of Kana resistant (final concentration 30 µg/ml) LB medium (Zhongaobio Company) at 37°C overnight. The plasmid DNA was extracted according the manufacturer’s instructions (Transgene company, Beijing, China). Plasmid DNA was quantified. Briefly, 2 µl of plasmid DNA and 98 µl of TE buffer (Tianjin Chemical Reagent Factory, Tianjin, China) were mixed. A nucleic acid quantifier (GeneQuant 80-2114-98, Cambridge, UK) was used to determine the concentration and record the absorbance ratio at 260 and 280 nm to assess the purity. Subsequent to detecting the concentration and purity, the plasmids were termed PAR-2 shRNA-1, PAR-2 shRNA-2 and non-specific sequences. The positive bacterium solution was sent to Shanghai Shangon Co., Ltd. (Shanghai, China) for identification by sequence technology.

**Cell culture and transfection.** EC109 cells were cultured with RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Minhai Biotech, Beijing, China) in a 5% CO₂ incubator at 37°C, and EC109 cells were digested with trypsin for passage following growth 80-90%. PAR-2 shRNA-1, PAR-2 shRNA-2 and non-specific sequences were transfected into cells in the logarithmic growth phase. Briefly, EC109 cells at logarithm phase were digested by trypsin and seeded into six-well plate (5x10⁴ per well). The cells were transfected when the growth reached 80% confluence. The cells and the transfected plasmids were incubated at 37°C for 24 h in the incubator. The blank control of EC109 cells received no transfection. The pGFP-V-RS plasmid with green fluorescent protein was observed using a Microscope Digital Camera DP27 (Olympus, Tokyo, Japan). The transfection efficiency was calculated based on the expression of green fluorescent protein (GFP) at 24 h post-transfection. The stably transfected cells were selected using 1.0 mg/ml puromycin by several passages. The EC109 cells without transfection were regarded as the blank control group. Other groups were named based on the transfection: PAR-2 shRNA-1 group; PAR-2 shRNA-2 group; and non-specific sequence group.

**Reverse transcription-polymerase chain reaction (RT-PCR).** Total RNA from cells at logarithmic phase was isolated in each group using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer’s protocol. The cDNA was synthesized from total RNA by reverse transcription with a Reverse Transcription System (Biometra UNO II Thermoblock; Biometra GmbH, Göttingen, Germany) and stored at -20°C. The reverse transcription conditions were 30°C for 10 min, 42°C for 30 min, 99°C for 5 min and 5°C for 5 min. The primers of PAR-2 and internal reference β-actin were designed by Omega 2.0 software (Accelrys, San Diego, CA, USA) as follows: PAR-2 forward, 5'-AGAAGCTTATTGGT AAGGTG-3' and reverse, 5'-AACATCATGACGTGCGT CAT-3', with amplification length 582 bp; and β-actin forward, 5’-TGGTGTAGACCTTTCAACCC-3’ and reverse, 5’-AGC ACTGTGTGGCCTACAGG-3’, with amplification length 540 bp. The reaction conditions of RT-PCR for PAR-2 used the RT-qPCR kit purchased from Beijing Transgen Biotech Co., Ltd. (Beijing, China), and the reaction included 35 cycles at 94°C for 45 sec, 51°C for 45 sec and 75°C for 1 min. The reaction conditions for β-actin were 35 cycles at 94°C for 45 sec, 55°C for 60 sec and 72°C for 45 sec. The PCR products were separated by 2% agarose gel electrophoresis and scanned using a GDS 8000 gel documentation system (UVP LLC, Upland, CA, USA). The relative expression of PAR-2 was calculated based on the expression of β-actin. The experiments were repeated three times.

**Western blot analysis.** The experimental cells (PAR-2 shRNA-1 EC109 cells, PAR-2 shRNA-2 EC109 cells, nonspecific sequence transfection EC109 cells and EC109 cells) were lysed with RIPA lysate (Beyotime institute of Biotechnology, Haimen, China) in each group and centrifuged at 3,000 x g and 4°C for 10 min to obtain supernatant. The protein concentration was detected by the bicinchoninic acid method using a BCA kit (Beyotime Institute of Biotechnology). Total proteins (80 µg) were loaded onto each well (six wells in total) of 10% SDS-PAGE and then transferred to polyvinylidene fluoride membranes. The membrane was washed with TBST and blocked with 5% skimmed milk at 37°C for 2 h. The primary antibody (rabbit mAb; cat. no. 6976; Cell Signaling Technology, Inc., Danvers, MA, USA; dilution, 1:1,000) was incubated at 37°C for 2 h, followed by incubation at 4°C overnight. This was then washed with TBST for 15 min four times. The secondary antibody (goat anti-rabbit; dilution, 1:1,000, Beijing Zhong Shan-Golden Bridge Biological Technology Co., Ltd., Beijing, China) was then added and incubated at 4°C for 2 h, and then washed with TBST for 15 min four times. Finally, the membrane was developed by enhanced chemiluminescence plus reagent (Beijing Dingguo Changshen Biotechnology co., Ltd., Beijing, China). The developed film was scanned and analyzed by Quantity One 4.62 software (Bio-Rad Laboratories, Inc., Hercules, CA, USA). β-actin was used as an internal control to calculate the relative expression of PAR-2.

**MTT assay.** In the MTT assay, three groups of EC109 cells were included: Negative control group (transfected with non-specific sequence vector); transfection reagent group (just adding transfection reagents); and PAR-2 shRNA group (PAR-2 downregulated group). The EC109 cells in different
groups were cultured in RPMI-1640 medium with 10% FBS at 37°C with 5% CO₂ for 24 h, and the cells in logarithmic growth phase were used for MTT assay. Cells in each group were seeded onto 96-well plates (2x10^3 per well). The 20 µl MTT solution with 5 mg/ml concentration was added to each well at 24, 48 and 72 h. Following culture for 4 h at 37°C, 200 µl dimethyl sulfoxide was added to end the reaction. The samples were analyzed using an ELISA analyzer (Biomad, Sacramento, CA, USA) and the absorbance of each well was measured at a wavelength of 490 nm. The ratio of inhibited growth was calculated by the formula: Ratio (%) = (absorbance (A) control - A experiment)/(A control-A blank) x100. The ratio of inhibited growth was used to draw cell growth inhibition curves.

Cell cycle analysis by flow cytometry. The cells in logarithmic phase were seeded into a culture flask at a density of 1x10^5/ml for 24 h at 37°C with 5% CO₂. The medium was then replaced with medium without FBS to culture for another 24 h at 37°C with 5% CO₂. The cells were collected by centrifugation 300 x g for 3 min at room temperature and washed twice with pre-cooled PBS. The 70% pre-cooled ethanol was added to fix at 4°C overnight. The cells were reserved at 4°C and subjected to propidium iodide staining and then the cell cycle was detected using BD flow cytometry (BD Biosciences, San Jose, CA, USA), and data was analyzed using ModFit LT for Windows Version 3.2 (Verity Software House, Topsham, ME, USA).

Transwell migration and Matrigel invasion assays. The migration and invasion assays were performed using Transwell chambers (EMD Millipore, Billerica, MA, USA). Matrigel was thawed at 4°C and mixed with serum-free medium with 1:4 ratio as an artificial basement membrane. The Transwell chamber with an 8 µm microporous membrane was placed in 24-well culture plates, and the upper chamber was uniformly covered with 40 µl artificial basement membrane (BD MatrigelTM Basement Membrane Matrix; BD Biosciences) mixed with RPMI-1640 at the ratio of 1:4. Subsequent to agglutination for 1 at 37°C h in an incubator, the moisture was absorbed from Matrigel to form a matrix barrier.

The cells were seeded into the upper chambers (2x10^5 cell/well), while 600 µl of medium containing 10% FBS was added to the bottom of the chamber. Each well had 3 replicates. Following culture at 37°C with 5% CO₂ for 28 h, cells were fixed using 10% formaldehyde at room temperature for 30 min, washed with PBS, and stained with eosin for 5 min at room temperature. The cells that could not pass through the membrane were wiped. Subsequent to natural drying, the membrane was then dried and moved to the slide and sealed by neutral balsam. Finally, images of the cells were captured under a light microscope (Olympus BX41; Olympus Corporation) with 5 random views. The number of migrated/invaded cells in the bottom chamber was counted and the average of 3 replicates was used. The experimental steps in the migration assay did not include use of Matrigel. The density of cell suspension was 1x10^5/ml.

Statistical analysis. Data are presented as the mean ± standard deviation, and were analyzed by SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA). The differences between two groups were determined by Student's t-test. Multi-group analysis was performed by one way analysis of variance, the post hoc test was the least significant difference test. P<0.05 was considered to indicate a statistically significant difference.

Results

Efficiency of cell transfection. The sequences of the PAR gene in vector were completely consistent with the PAR-2 target
sequences. Following transfection for 24 h, the expression of green fluorescence was observed by inverted fluorescence microscopy, as shown in Fig. 1. The transfection efficiency was calculated by the percentage of the number of cells expressing green fluorescence among the total number of cells. The mean transfection efficiency of PAR-2 shRNA-1, PAR-2 shRNA-2 and non-specific sequence group was 67.6%, while no green fluorescence was observed in the blank control group.

PAR-2 expression in different EC109 cell lines by RT-PCR and western blot analysis. To detect PAR-2 mRNA expression following transfection, RT-PCR was applied to different groups. As shown in Fig. 2A, the band intensities were 0.35±0.03, 0.43±0.04, 0.44±0.04 and 0.45±0.41 in PAR-2 shRNA-1 group, PAR-2 shRNA-2 group, non-specific sequence group and blank control group, respectively. Compared with the other three groups, PAR-2 was significantly downregulated in the PAR-2 shRNA-1 group (P<0.05). Among the PAR-2 shRNA-2 group, non-specific sequence group and blank control group, PAR-2 mRNA expression had no significant difference (P>0.05). The results indicated that the constructed PAR-2 shRNA-1 recombinant vector efficiently silenced PAR-2 mRNA.

PAR-2 protein expression subsequent to transfection with recombinant vectors, western blot analysis was performed in different groups. As shown in Fig. 2B, the grey intensities were 0.96±0.01, 1.04±0.02, 1.05±0.04 and 1.09±0.04 in the PAR-2 shRNA-1, PAR-2 shRNA-2, non-specific sequence and blank control groups, respectively. Compared with the other three groups, PAR-2 was significantly decreased in the PAR-2 shRNA-1 group (P<0.05). Among the PAR-2 shRNA-2 group, non-specific sequence group and blank control group, PAR-2 protein expression had no significant difference (P>0.05). The results indicated that the constructed PAR-2 shRNA-1 recombinant vector could efficiently silence PAR-2 expression, which was consistent with PAR-2 mRNA expression.

EC109 cell viability by MTT assay. For studying the effect of PAR-2 on cell viability, a MTT assay was used to detect the changes of proliferation following transfection. As shown in Fig. 3, EC109 cell proliferation in the PAR-2 shRNA group was significantly lower than the negative control group (P<0.05), and the growth inhibition ratios were 5.92, 24.89 and 32.28% at 24, 48 and 72 h post-transfection, respectively. Between
the transfection reagent group and the negative control group, no significant difference was observed (P>0.05). The results indicated that silenced PAR-2 can repress cellular proliferation in EC109 cell lines, while the transfection reagent and negative plasmid have no significant inhibition roles in EC109 cell viability.
The expression of PAR-2 is highly expressed in a variety of gastrointestinal cancer cells, expressed in various tissues and organs in the body, and is a critical activator of the thrombin receptor. PAR-2 is widely identified in mice, which was the initial discovery of DNA sequence of PAR-2 in mice, which was associated with regulators of the cell cycle. In 1994, Nystedt et al. demonstrated that PAR-2 can promote invasion and metastasis in colorectal and gastric cancers (11,12). It was revealed that PAR-2 can be activated by a variety of molecules, including trypsin, human airway trypsin-like protease, sperm acrosin, cathepsin G, tissue factor Xa and activated coagulation factor VIIa and Xa in vivo (8,13,14), and trypsin is one of the most effective activators (9). Among tumors in the digestive system, activated PAR-2 can promote invasion and metastasis of tumor cells, regulate tumor cell proliferation, adhesion and angiogenesis (15,16).

**Discussion**

Protease-activated receptors (PARs) belong to a G protein-coupled receptor superfamily with seven transmembrane domains, which includes four subtypes: PAR-1, PAR-2, PAR-3 and PAR-4 (5). All the subtypes contain N-terminus, extracellular loop, seven transmembrane helix, intracellular loop and C-terminal regions (5). The serine cleavage site is hidden in the N-terminus of the PARs, which serves important roles in activated processes (9). In 1994, Nystedt et al. identified the DNA sequence of PAR-2 in mice, which was named PAR-2 as it shared a similar structure and activating mechanism to thrombin receptor. PAR-2 is widely expressed in various tissues and organs in the body, and is highly expressed in a variety of gastrointestinal cancer cells, including esophageal, liver, stomach, pancreatic and colorectal cancers, which are associated with the morbidity, progression and prognosis of tumors (11,12).

RNA interference (RNAi) refers to post-transcriptional silencing processes induced by specific sequences, which can inhibit mRNA expression mediated by small interfering RNA (siRNA) (17). When viral or exogenous genes were randomly integrated into the host genome, double-stranded RNA (dsRNA) was produced, and these dsRNA can be cut into small interfering RNA fragments (siRNAs) 21-23 bp in length by Dicer (18). Under RNA helicase processing, siRNA antisense can form into an RNA-induced silencing complex (RISC) with different enzymes (19). Based on complementary binding, RISC can combine with target mRNA sequences, then the mRNA was cut at position with 12 bp of siRNA 3’ end. The cut mRNA was degraded, which induced post-transcriptional gene silencing (18-20). RNAi is one of the most efficient and specific gene silencing mechanisms, which is becoming an effective targeting gene therapy for tumors (21). In the present study, a pGFP-V-RS vector containing PAR-2 shRNA was constructed and transfected into EC109 cells. Following selection by puromycin, stably-transfected EC109 cells were validated by RT-PCR and western blot analysis. PAR-2 was downregulated in mRNA level and protein level, which indicated that recombinant siRNA vector was successfully constructed. It was revealed that activated PAR-2 induces DNA synthesis and cell division (22). MTT assay was applied to detect the proliferation of EC109 cells subsequent to silencing PAR-2. It was revealed that silenced PAR-2 repressed cell proliferation. Through flow cytometry, S phase arrest was observed in PAR-2 silenced cells. Additional studies are required to investigate whether repression of cell proliferation induced by PAR-2 silencing was associated with regulators of the cell cycle.

Besides local proliferation and infiltration, tumor cells will invade to other distant tissues (8). Cell invasion and metastasis in tumors is a complex and continuous process, among which extracellular matrix degradation is a key step (23). Matrix metalloproteinases (MMPs) are a class of Zn2+ dependent proteolytic enzymes, which can be expressed and secreted in tumor cells and stromal cells, resulting in tumor invasion and metastasis (24). In previous years, it was shown that PAR-2 can promote tumor growth, invasion and metastasis through activation of MMP pathways (24). Through promoting the release of transforming growth factor-α, activating epithelial growth factor receptor and kinase extracellular signal-regulated kinase 1/2, PAR-2 can promote cellular proliferation, invasion and metastasis in colorectal and gastric cancers (24,25). Our previous study revealed that PAR-2 can promote invasion and metastasis of HepG2 cells through degrading extracellular matrix by the PAR-2-focal adhesion kinase-MMP-2/9 pathway (8). By RT-PCR, immunohistochemistry and zymography methods, Zhou et al. found that PAR-2 receptor 2. and normal cultured cells were 19.37±2.19, 16.93±2.56 and 18.74±2.92% and 32.79±4.06, 26.54±1.37 and 33.45±2.46% after 24, 48 and 72 h, respectively. The ratio of S phase cells was significantly lower in EC109 cells transfected with PAR-2 shRNA than in EC109 cells (P<0.05), which indicated that silenced PAR-2 inhibited cell cycle of EC109 cells.

**Table I. Effects of PAR-2 on invasion and migration of silenced and normal EC109 cells.**

| Cell number of Transwells | Invasion     | Migration   |
|---------------------------|-------------|-------------|
| Silenced                  | 19.6±2.11a  | 24.2±2.82a  |
| Control                   | 30.1±2.64   | 43.8±2.14   |

*aP<0.01 vs. the control group. (± standard deviation, n=10). PAR-2, protease-activated receptor 2.

**Discussion**

Protease-activated receptors (PARs) belong to a G protein-coupled receptor superfamily with seven transmembrane domains, which includes four subtypes: PAR-1, PAR-2, PAR-3 and PAR-4 (5). All the subtypes contain N-terminus, extracellular loop, seven transmembrane helix, intracellular loop and C-terminal regions (5). The serine cleavage site is hidden in the N-terminus of the PARs, which serves important roles in activated processes (9). In 1994, Nystedt et al. (10) identified the DNA sequence of PAR-2 in mice, which was named PAR-2 as it shared a similar structure and activating mechanism to thrombin receptor. PAR-2 is widely expressed in various tissues and organs in the body, and is highly expressed in a variety of gastrointestinal cancer cells, including esophageal, liver, stomach, pancreatic and colon cancers, which are associated with the morbidity, progression and prognosis of tumors (11,12). It was revealed that PAR-2 can be activated by a variety of molecules, including trypsin, human airway trypsin-like protease, sperm acrosin, cathepsin G, tissue factor Xa and activated coagulation factor VIIa and Xa in vivo (8,13,14), and trypsin is one of the most effective activators (9). Among tumors in the digestive system, activated PAR-2 can promote invasion and metastasis of tumor cells, regulate tumor cell proliferation, adhesion and angiogenesis (15,16).

RNA interference (RNAi) refers to post-transcriptional silencing processes induced by specific sequences, which can inhibit mRNA expression mediated by small interfering RNA (siRNA) (17). When viral or exogenous genes were randomly integrated into the host genome, double-stranded RNA (dsRNA) was produced, and these dsRNA can be cut into small interfering RNA fragments (siRNAs) 21-23 bp in length by Dicer (18). Under RNA helicase processing, siRNA antisense can form into an RNA-induced silencing complex (RISC) with different enzymes (19). Based on complementary binding, RISC can combine with target mRNA sequences, then the mRNA was cut at position with 12 bp of siRNA 3’ end. The cut mRNA was degraded, which induced post-transcriptional gene silencing (18-20). RNAi is one of the most efficient and specific gene silencing mechanisms, which is becoming an effective targeting gene therapy for tumors (21). In the present study, a pGFP-V-RS vector containing PAR-2 shRNA was constructed and transfected into EC109 cells. Following selection by puromycin, stably-transfected EC109 cells were validated by RT-PCR and western blot analysis. PAR-2 was downregulated in mRNA level and protein level, which indicated that recombinant siRNA vector was successfully constructed. It was revealed that activated PAR-2 induces DNA synthesis and cell division (22). MTT assay was applied to detect the proliferation of EC109 cells subsequent to silencing PAR-2. It was revealed that silenced PAR-2 repressed cell proliferation. Through flow cytometry, S phase arrest was observed in PAR-2 silenced cells. Additional studies are required to investigate whether repression of cell proliferation induced by PAR-2 silencing was associated with regulators of the cell cycle.

Besides local proliferation and infiltration, tumor cells will invade to other distant tissues (8). Cell invasion and metastasis in tumors is a complex and continuous process, among which extracellular matrix degradation is a key step (23). Matrix metalloproteinases (MMPs) are a class of Zn2+ dependent proteolytic enzymes, which can be expressed and secreted in tumor cells and stromal cells, resulting in tumor invasion and metastasis (24). In previous years, it was shown that PAR-2 can promote tumor growth, invasion and metastasis through activation of MMP pathways (24). Through promoting the release of transforming growth factor-α, activating epithelial growth factor receptor and kinase extracellular signal-regulated kinase 1/2, PAR-2 can promote cellular proliferation, invasion and metastasis in colorectal and gastric cancers (24,25). Our previous study revealed that PAR-2 can promote invasion and metastasis of HepG2 cells through degrading extracellular matrix by the PAR-2-focal adhesion kinase-MMP-2/9 pathway (8). By RT-PCR, immunohistochemistry and zymography methods, Zhou et al. (8) found that PAR-2 receptor
expressed in EC109 cells, and appropriate concentrations of SLIGKV and trypsin can activate PAR-2 receptor to increase the expression level. Therefore, this promotes cell invasion and metastasis of EC109 cells by promoting MMP-9 secretion and degradation of the extracellular matrix. In the present study, Matrigel and Transwell assays were applied to detect the changes of cell invasion and metastasis of EC109 cells following PAR-2 silencing. It was indicated that the capabilities of cell invasion and metastasis were decreased subsequent to PAR-2 gene silencing. The molecular mechanisms and associated signaling transduction pathways require additional exploration.

In summary, PAR-2 can be downregulated in EC109 cells through RNAi technology. The capabilities of cellular proliferation, invasion and metastasis were decreased following the downregulation of PAR-2 expression. Although it remains unclear whether PAR-2 is involved in repressing the capabilities of cell invasion and metastasis in EC109 cells subsequent to gene silencing, PAR-2 target silence by RNAi technology may become a new candidate for treatment in esophageal cancers.

Acknowledgements

The present study was supported by the Hospital-Level Seed Fund Project of the Affiliated Hospital of Medical School of the Armed Police (grant no. FYM201115).

References

1. Montgomery EA: Oesophageal cancer. In: World Cancer Report 2014, Stewart BW and Wild CP (eds), IARC, Lyon, 374-382, 2014.
2. Hao J and Shao K: The epidemiology, current status of management, challenge and future strategy for esophageal cancer. Chin Oncol 21: 501-504, 2011.
3. Ciocirlan M, Lapalus MG, Hervieu V, Souquet JC, Napoléon B, Scoazec JY, Lefort C, Saurin JC and Ponchon T: Endoscopic mucosal resection for squamous premalignant and early malignant lesions of the esophagus. Endoscopy 39: 24-29, 2007.
4. Kim T, Grobmyer SR, Smith R, Ben-David K, Ang D, Vogel SB and Hochwald SN: Esophageal cancer-the five year survivors. J Surg Oncol 103: 179-183, 2011.
5. Ossovskaya VS and Bunnett NW: Protease-activated receptors: Contribution to physiology and disease. Physiol Rev 84: 579-621, 2004.
6. Caruso R, Pallone F, Fina D, Gioia V, Peluso I, Caprioli F, Stolfi C, Perfetti A, Spagnoli LG, Palmieri G, et al: Protease-activated receptor-2 activation in gastric cancer cells promotes epithelial growth factor receptor transactivation and proliferation. Am J Pathol 169: 268-278, 2006.
7. Shimamoto R, Sawada T, Uchima Y, Inoue M, Kimura K, Yamashita Y, Yamada N, Nishihara T, Ohira M and Hirakawa K: A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. Int J Oncol 24: 1401-1406, 2004.
8. Zhou J, Xie LQ, Li X, Chen X, Chen L, Zheng Y, Li F: Protease-activated receptor-2 agonists promote cell invasion and metastasis in human esophageal cancer cell line EC109. World Chin J Digestol 13: 1313-1319, 2010 (In Chinese).
9. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD and Plevin R: Proteinase-activated receptors. Pharmacol Rev 53: 245-282, 2001.
10. Nystedt S, Emilsson K, Wahlestedt C and Sundelin J: Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci USA 91: 9208-9212, 1994.
11. Inci K, Ededo A, Olbe L and Casselbrant A: Expression of protease-activated-receptor 2 (PAR-2) in human esophageal mucosa. Scand J Gastroenterol 44: 664-671, 2009.
12. Uchima Y, Sawada T and Hirakawa K: Action of antiproteases on pancreatic cancer cells. JOP 8 (4 Suppl): S479-S487, 2007.
13. Uusitalo-Jarvinen H, Kurokawa T, Mueller BM, Andrade-Gordon P, Friedlander M and Ruf W: Role of protease activated receptor 1 and 2 signaling in hypoxia induced angiogenesis. Arterioscler Thromb Vasc Biol 27: 1456-1462, 2007.
14. Awasthi V, Mandal SK, Papanna V, Rao LV and Pendarurthi UR: Modulation of tissue factor VIIa signaling by lipid rafts and caveolae. Arterioscler Thromb Vasc Biol 27: 1447-1455, 2007.
15. Fujiimoto D, Hirono Y, Gori T, Katayama K, Hirose K and Yamaguchi A: Expression of protease activated receptor-2 (PAR-2) in gastric cancer. J Surg Oncol 93: 139-144, 2006.
16. Ribeiro FS, Simão TA, Amôêdo ND, Andreollo NA, Lopes LR, Acatauassu R, Rumjanek FD, Albano RM, Pinto LF and Monteiro RQ: Evidence for increased expression of tissue factor and protease-activated receptor-1 in human esophageal cancer. Oncol Rep 21: 1599-1604, 2009.
17. Hannon GJ: RNA interference. Nature 418: 244-251, 2002.
18. Brusselmans K, De Schrijver E, Verhoeven G and Swinnen JV: RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 65: 6719-6725, 2005.
19. Filipowicz W: RNAi: The nuts and bolts of the RISC machine. Cell 122: 17-20, 2005.
20. Mette MF, Aufsatz W, Kanno T, Daxinger L, Rovina P, Matzke M and Matzke AJ: Analysis of double-strand RNA and small RNAs involved in RNA-mediated transcriptional gene silencing. Methods Mol Biol 309: 61-82, 2005.
21. Zhang H, Zheng X, Chen K, et al: siRNA inhibit the expression of VEGF-C in patients with esophageal carcinoma. Cancer Res Prev Treatment 37: 132-135, 2010 (In Chinese).
22. Zheng YM, Xie LQ, Zhao JY, Li X, Chen XY, Chen L, Hai O and Zhou J: Effects of proteinase activated receptor-2 agonists on proliferation of hepatoma cells. Zhonghua Gan Zang Bing Za Zhi 17: 701-702, 2009 (In Chinese).
23. Zeng ZS, Shu WP, Cohen AM and Guillem JG: Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: Evidence for involvement of MMP-7 activation in human cancer metastases. Clin Cancer Res 8: 144-148, 2002.
24. Caruso R, Pallone F, Fina D, Gioia V, Peluso I, Caprioli F, Stolfi C, Perfetti A, Spagnoli LG, Palmieri G, et al: Protease-activated receptor-2 activation in gastric cancer cells promotes epithelial growth factor receptor trans-activation and proliferation. Am J Pathol 169: 268-278, 2006.
25. Darmoul D, Gratio V, Devaud H and Laburthe M: Protease-activated receptor 2 in colon cancer: Tryptsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem 279: 20927-20934, 2004.